

UCSF

UC San Francisco Previously Published Works

Title

Discovery of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimers disease.

Permalink

<https://escholarship.org/uc/item/63r3n2vq>

Journal

Journal of Biological Chemistry, 299(12)

Authors

Du, Yuhong

Bradshaw, William

Leisner, Tina

et al.

Publication Date

2023-10-21

DOI

10.1016/j.jbc.2023.105382

Peer reviewed



# Discovery of FERM domain protein–protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimer's disease

Received for publication, May 22, 2023, and in revised form, September 11, 2023. Published, Papers in Press, October 21, 2023.

<https://doi.org/10.1016/j.jbc.2023.105382>

Yuhong Du<sup>1,2,‡</sup>, William J. Bradshaw<sup>3,‡</sup>, Tina M. Leisner<sup>4,‡</sup>, Joel K. Annor-Gyamfi<sup>5,‡</sup>, Kun Qian<sup>1,2</sup>, Frances M. Bashore<sup>3</sup>, Arunima Sikdar<sup>4</sup>, Felix O. Nwogbo<sup>4</sup>, Andrey A. Ivanov<sup>1,2</sup>, Stephen V. Frye<sup>4</sup>, Opher Gileadi<sup>3</sup>, Paul E. Brennan<sup>3</sup>, Allan I. Levey<sup>6</sup>, the Emory-Sage-SGC TREAT-AD Center<sup>§</sup>, Alison D. Axtman<sup>5,\*</sup>, Kenneth H. Pearce<sup>4,\*</sup>, Haian Fu<sup>1,2,\*</sup>, and Vittorio L. Katis<sup>3,\*</sup>

From the <sup>1</sup>Department of Pharmacology and Chemical Biology, and <sup>2</sup>Emory Chemical Biology Discovery Center, Emory University School of Medicine, Atlanta, Georgia, USA; <sup>3</sup>Alzheimer's Research UK Oxford Drug Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine Research Building, University of Oxford, Oxford, UK; <sup>4</sup>Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, Center for Integrative Chemical Biology and Drug Discovery, Chapel Hill, North Carolina, USA; <sup>5</sup>Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, Structural Genomics Consortium, Chapel Hill, North Carolina, USA; <sup>6</sup>Department of Neurology, Emory Goizueta Alzheimer's Disease Research Center, Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia, USA

Reviewed by members of the JBC Editorial Board. Edited by Phillip A. Cole

Proteomic studies have identified moesin (MSN), a protein containing a four-point-one, ezrin, radixin, moesin (FERM) domain, and the receptor CD44 as hub proteins found within a coexpression module strongly linked to Alzheimer's disease (AD) traits and microglia. These proteins are more abundant in Alzheimer's patient brains, and their levels are positively correlated with cognitive decline, amyloid plaque deposition, and neurofibrillary tangle burden. The MSN FERM domain interacts with the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) and the cytoplasmic tail of CD44. Inhibiting the MSN–CD44 interaction may help limit AD-associated neuronal damage. Here, we investigated the feasibility of developing inhibitors that target this protein–protein interaction. We have employed structural, mutational, and phage-display studies to examine how CD44 binds to the FERM domain of MSN. Interestingly, we have identified an allosteric site located close to the PIP<sub>2</sub> binding pocket that influences CD44 binding. These findings suggest a mechanism in which PIP<sub>2</sub> binding to the FERM domain stimulates CD44 binding through an allosteric effect, leading to the formation of a neighboring pocket capable of accommodating a receptor tail. Furthermore, high-throughput screening of a chemical library identified two compounds that disrupt the MSN–CD44

interaction. One compound series was further optimized for biochemical activity, specificity, and solubility. Our results suggest that the FERM domain holds potential as a drug development target. Small molecule preliminary leads generated from this study could serve as a foundation for additional medicinal chemistry efforts with the goal of controlling microglial activity in AD by modifying the MSN–CD44 interaction.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that results in dementia, affecting over 50 million people worldwide (1). AD pathology is characterized by the build up within the brain of amyloid beta–containing senile plaques and the formation of neurofibrillary tangles composed of hyperphosphorylated tau. Despite the clear involvement of dysregulated amyloid beta in AD pathogenesis as demonstrated by preclinical and clinical studies, recent attempts to target amyloid beta in phase III clinical trials have predominantly yielded varied outcomes in terms of slowing down cognitive decline (2–4). As our understanding of the complex pathophysiology of AD remains incomplete, there is a need to explore the role of other potential proteins in the disease and to evaluate their therapeutic feasibility. In recent years, inflammatory signaling within microglia has received increasing attention for its role in AD pathology (5), with a number of proteins linked to microglial signaling identified as potential drug targets (6). Chronic activation of microglia can lead to the production of toxic cytokines and chemokines, which cause neuronal damage. Suppressing microglial-mediated inflammation may be an important strategy in the treatment of AD.

To gain a more comprehensive understanding of AD biology, Johnson *et al.* (2020) utilized an unbiased proteomics approach to examine tissue from more than 400 human brains.

<sup>‡</sup> These authors contributed equally to this work.

<sup>§</sup> Full list of members of the Emory-Sage-SGC TREAT-AD Center are available in [Supplementary information](#).

\* For correspondence: Alison D. Axtman, [alison.axtman@unc.edu](mailto:alison.axtman@unc.edu); Kenneth H. Pearce, [khpearce@unc.edu](mailto:khpearce@unc.edu); Haian Fu, [hfu@emory.edu](mailto:hfu@emory.edu); Vittorio L. Katis, [vittorio.katis@cmd.ox.ac.uk](mailto:vittorio.katis@cmd.ox.ac.uk).

Present addresses for: Kun Qian, Chemical Biology Consortium Sweden, Division of Chemical Biology and Genome Engineering, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 171 65 Solna, Sweden; Opher Gileadi, Structural Genomics Consortium, Department of Medicine, Karolinska Hospital and Karolinska Institute, 171 76 Stockholm, Sweden.

## Discovery of MSN–CD44 interaction inhibitors for AD

Coexpression network analysis identified a module (M4) that was enriched with AD risk genes and proteins expressed in both astrocytes and microglia (7, 8). Within this module, two hub proteins, moesin (MSN) and CD44, were found to have strongly correlated expression with cognition, amyloid plaque and neurofibrillary tangle burden. Given the module's enrichment in genes associated with AD risk, these hub proteins are considered as causal drivers in disease progression (9). Protein levels of MSN and CD44 are elevated in AD brains, with CD44 levels enriched in AD patient cerebral spinal fluid (7, 9). MSN, which is predominantly produced in microglial cells in the brain, was often observed surrounding amyloid beta plaques in AD patients and the 5xFAD mouse model (8). CD44, on the other hand, is produced in both neuronal and glial cells, where it is involved in neuro-inflammation (10, 11). Loss-of-function studies highlight a role for CD44 in amyloid-beta induced neurotoxicity (12).

The ezrin radixin moesin (ERM) family of proteins, to which MSN belongs, is involved in linking the actin cytoskeleton to the plasma membrane (13, 14). This allows ERM proteins to regulate cytoskeletal rearrangements that govern various cellular functions, including migration, motility, cell shape, and signaling. ERM proteins are localized to specialized phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>)-enriched regions within the membrane (15, 16), where their N-terminal four-point-one ezrin radixin moesin (FERM) domain binds to PIP<sub>2</sub> and the cytoplasmic C-terminal tails of receptor proteins like CD44. The C-terminal domain of ERM proteins blocks the binding of CD44 to the FERM domain when in an inactive conformation (17, 18). However, phosphorylation of this inhibitory domain results in its dissociation from the FERM domain, enabling it to bind to CD44 (19) (as depicted in Fig. 1A). The FERM domain is made up of three subdomains (F1, F2, and F3) that form a “three-leaf clover” topology. Structural investigations of mouse radixin indicate that CD44 binds to subdomain F3 (20). CD44, a cell surface glycoprotein, is a receptor for hyaluronic acid, a crucial component of the extracellular matrix in different organs, including the brain. By associating with ERM proteins, the binding of CD44 to hyaluronic acid through its extracellular domain is believed to promote cell adhesion and migration (21).

The above evidence suggests that both MSN and CD44 are involved in the inflammatory response observed in the brains of AD patients. Although it is unclear if MSN plays a detrimental or protective function in AD pathogenesis (8), inhibition of the interaction between these two proteins is proposed to reduce neuronal damage by hyperactive microglia. In this study, we explore the tractability of developing small molecule inhibitors that disrupt the interaction of the FERM domain of MSN with CD44. Cocystallography revealed the FERM domain binds to the cytoplasmic tail of CD44 in a similar fashion to that seen previously with radixin (20). A simple and robust biochemical assay based on time-resolved FRET (TR-FRET) was developed to measure the MSN–CD44 interaction. High-throughput screening identified two compounds that could displace this interaction, both *in vitro* and *in cellulo*. Further optimisation improved biochemical activity, specificity

and solubility of one of these compounds. To investigate whether MSN–CD44 protein–protein interaction (PPI) inhibitors could be obtained that bind at allosteric sites on the FERM domain, we employed a peptide phage-display library. In conclusion, this study demonstrates that the FERM domain is a viable target for drug development, and further refinement of preliminary leads could provide valuable insight into the role of MSN and CD44 in AD.


## Results

### High-resolution structure of MSN FERM domain

To assist our efforts in obtaining MSN–CD44 PPI inhibitors, we determined the crystal structure of the FERM domain of human MSN to a resolution of 1.73 Å (Fig. 1B, PDB: 6TXQ) (Table S1). We compared our structure to a previously published lower resolution MSN FERM-domain crystal structure (1E5W; 2.7 Å) (22). The characteristic FERM domain fold was evident in both structures, where the subdomains F1, F2, and F3 adopted a shape reminiscent of a clover. Despite sharing the same overall topology, there were notable differences between the two structures (Fig. S1A). In our structure, the F3 lobe was significantly moved away from the F1 subdomain, which was rotated by 12° along the long alpha helix (Fig. S1B). While the F1 and F2 subdomains were very similar between both structures, significant changes were observed within the F3 lobe (Fig. S1C). The F3 subdomain contains a pocket between the extended helix ( $\alpha$ 1) and beta-sheet ( $\beta$ 5– $\beta$ 7) that binds diverse receptor tail ligands. In our structure, this pocket was in a “closed” conformation, which could not accommodate a receptor tail. In contrast, the previous MSN-FERM structure (1E5W) had a more “open” F3 subdomain with the beta-sheet displaced from the helix by 2.5 Å (Fig. S1C). The variable positions of the subdomains observed in the two MSN FERM structures suggest they have a high degree of independent movement within the FERM domain.

### Structure of MSN FERM domain bound to CD44

We have successfully determined a crystal structure of the FERM domain of MSN in complex with a short peptide that includes the ERM-binding region of CD44's cytoplasmic tail, solved to 2.2 Å (Fig. 1C; PDB:6TXS) (Table S1). Within the F3 lobe of MSN, CD44 forms a beta strand that sits adjacent to the extended helix, contributing to the  $\beta$ 5– $\beta$ 7 antiparallel beta-sheet. This type of interaction was also seen in a previous study where a CD44 peptide was bound to radixin (20), an ERM protein that is closely related to MSN (2ZPY). Comparison of the CD44-bound and ligand-free MSN structures revealed that peptide binding led to a significant displacement of the  $\beta$ 5– $\beta$ 7 beta-sheet from the alpha helix (2 Å), as shown in Figure 1D. The interaction between CD44 and MSN is mainly through backbone–backbone hydrogen bonds with the MSN  $\beta$ 5 strand. Additionally, the CD44 peptide backbone can form hydrogen bonds with the H288 side chain within the extended alpha helix and salt bridges to the R246 and D252 side chains within the  $\beta$ 5 strand (Fig. 1E). Interestingly, the R246 and D252 interactions were not observed in the radixin-CD44 structure (20), although these residues are conserved between both ERM



**Figure 1. Crystal structure of MSN-FERM, either ligand free, or bound to CD44 cytoplasmic tail.** *A*, model showing MSN activation through binding the C-terminal cytoplasmic tail of the CD44 receptor and PIP<sub>2</sub>. *B*, crystal structure of ligand-free FERM domain of human MSN (PDB: 6TXQ). The three FERM subdomains of MSN, shown as *ribbons*, are colored in *green* (F1), *metallic blue* (F2), and *wheat color* (F3), while the long C-terminal alpha helix is colored in *gray*. *C*, crystal structure of human MSN bound to a short synthetic CD44 peptide (678-QKKLVIN-685). CD44 (*magenta, ribbon*) binds within the F3 domain, forming part of the beta-sheet. *D*, CD44 within the F3 lobe (*magenta, stick model*) is accommodated by a displacement of the beta-sheet away from the alpha helix by 2.0 Å, measured from H288 and R246 carbonyl carbon atoms. MSN bound to CD44 is shown in *wheat colour*, while unbound MSN is shown in *cyan*. *E*, interactions between MSN and CD44, showing hydrogen bonding (*green dashed lines*). The majority of bonding is backbone-backbone, although a few MSN side chain residue interactions (H288, D252, R246) were identified. The MSN-K278 interaction is most likely an artefact of crystal packing. *F*, overlay of the FERM domain-bound CD44 to either MSN (this work) or radixin (PDB: 2ZPY). FERM, four-point-one ezrin radixin moesin; MSN, moesin; PIP<sub>2</sub>, phosphatidylinositol 4,5-bisphosphate.


proteins. The CD44-bound structures of both ERM proteins were found to have closely aligned peptide backbones, although the three lysine residues within the CD44 peptide were spread out in our structure, forming a large hydrophobic surface (Fig. 1F). While the electron density of the lysine side chains from the radixin-CD44 structure was considerably weaker, our structure provided clear density (Fig. S2) with better B-factors for these side chains (2ZPY: 60–80 Å<sup>2</sup>; 6TXS: 40–50 Å<sup>2</sup>). When bound to MSN, the 8-residue CD44 peptide was found to have a total buried surface area of 1392 Å<sup>2</sup>.

#### A MSN TR-FRET assay reveals residues important for CD44 binding

A TR-FRET assay was established to measure the binding of CD44 peptide to MSN. The assay generated a specific FRET

signal from purified 6His-tagged MSN bound to terbium and an FITC-conjugated CD44 peptide (Fig. 2A). The specificity of the TR-FRET signal was confirmed by titration with increasing concentrations of unlabeled CD44 peptide (Fig. 2B). Site-directed mutagenesis was used to validate and disrupt the CD44 interaction observed in the structure. However, due to the lack of MSN side chain interactions to the peptide, we focussed our efforts on H288, a conserved residue among both ERM proteins and more distantly related FERM domain proteins, such as 4.1 B and FRMD6. H288, which forms a hydrogen bond to the carbonyl of CD44 residue I684, was mutated to alanine. In addition, we mutated S249, L281, and M286 to arginine, a bulky charged residue that we predicted would cause steric hindrance with CD44 binding. While S249R and M286R showed no effect (not shown), H288A and L281R

## Discovery of MSN-CD44 interaction inhibitors for AD



**Figure 2. Structure-guided mutagenesis reveals MSN residues involved in CD44 binding.** *A*, schematic representation of the *in vitro* TR-FRET assay for MSN-CD44 interaction using purified components. Signal generated from Tb-linked anti-6His antibody bound to MSN is transferred to the FITC-conjugated CD44 peptide. *B*, inhibition of the TR-FRET signal using unlabeled CD44 peptide as a competitor (IC<sub>50</sub> = 66 nM). *C*, side chains of mutated MSN residues (L281R and H288R) within the MSN-CD44 binding pocket are shown (green). *D*, comparison of MSN-CD44 TR-FRET response using varying levels of 6His-tagged WT or MSN mutant protein (0.01–0.29 nM). CD44 peptide concentration was kept constant (8 nM). *E*, competition of mutant MSN protein in MSN-CD44 TR-FRET assay. Dose response of untagged WT or mutant MSN protein in TR-FRET assay containing WT 6His-MSN (2 nM) and CD44 peptide (8 nM). IC<sub>50</sub> values of competitor proteins are shown on the right (*n* = 3). *F*, thermal shift assay, showing melting temperature ( $T_m$ ) curves of WT, and mutant proteins (left panel). The  $\Delta T_m$ , compared to WT protein, is shown in the right panel (*n* = 3;  $\pm$ SD). MSN, moesin; PPI, protein-protein interaction; TR-FRET, time-resolved FRET.


mutations resulted in weak TR-FRET signals compared to WT MSN (Fig. 2D) and required a 10-fold higher concentration to inhibit the WT MSN-CD44 interaction in a competition assay (Fig. 2E). The mutants showed minimal changes in melting temperature in a thermal shift assay (Fig. 2F) and crystal structures of MSN H288A and L281R mutant FERM domains confirmed that they were correctly folded (Fig. S3) (Table S1).

### Phage display identifies peptides that bind to the MSN FERM domain at two distinct sites

To investigate possible allosteric binding pockets on the FERM domain of MSN that could affect CD44 interaction, we performed phage display screening using a library that contained a randomized 10-amino acid sequence. We screened the library both with and without the CD44 peptide and

tracked each round of selection by monitoring colony formation units and phage ELISA. After examining the sequences of the clones that were identified as positive by ELISA, we discovered two peptides, C3P-pd and C3S1-pd, which were selected in the presence and absence of the CD44 peptide, respectively (Fig. 3A).

A crystal structure of C3P-pd bound to MSN was determined (1.85 Å), which revealed the peptide binds to a crevice situated between the F1 and F3 subdomains, adjacent to the proposed PIP<sub>2</sub> binding pocket (Figs. 3, B and G, and S4A) (Table S1). The peptide adopted an unusual compact structure that formed a plug between the two subdomains, supported by multiple internal hydrogen bonds, including the one formed between the indole nitrogen of W6 and two carbonyl groups within the peptide backbone. The peptide interacted with both subdomains *via* several hydrogen bonds (Fig. 3C). Specifically, within the F1



**Figure 3. Phage display screening identifies peptides that bind MSN at distinct sites.** *A*, sequences of phage display peptides. *Underlined region* corresponds to the variable region within the phage-derived sequence. *B*, crystal structure of FERM domain of MSN bound to the C3P-pd peptide. FERM subdomains are displayed as in 1B. C3P-pd peptide (*magenta*) binds in a pocket between the F1 and F3 subdomains. *C*, close-up view of C3P-pd peptide bound to MSN. Peptide intramolecular H-bonds are shown (*purple dashed lines*). Side chains of MSN residues interacting with the peptide, together with their bonding to the peptide (*gold dashed lines*). *D*, superimposed F3 subdomains of MSN from apo (*cyan*) and C3P-pd bound (*light yellow*) structures. C3P-pd peptide binding causes a 2.3 Å movement of the beta-sheet away from the alpha helix in the MSN F3 lobe, measured from H288 and R246 carbonyl carbon atoms. *E*, crystal structure of FERM domain of MSN bound to both C3P-pd and C3S1-pd peptides. *F*, close-up of C3S1-pd binding to F3 lobe of MSN. H-bond contacts are shown (*green dashed lines*). *G*, space-filling model of MSN FERM domain, showing C3P-pd (*magenta*) and CD44 (*cyan*) binding relative to proposed PIP<sub>2</sub> binding pocket (PIP<sub>2</sub>-BP; *blue positively charged surface*). *H–J*, MSN TR-FRET inhibition assays, with acceptor fluorophore conjugated to either (*H*) CD44, (*I*) C3P-pd, or (*J*) C3S1-pd peptides. Unlabeled peptides were used as competitors (C3S1-pd, *blue circle*; C3P-pd, *red square*;

## Discovery of MSN–CD44 interaction inhibitors for AD

subdomain, C3P-pd interacted with the N62 and K83 side chains. Within the F3 subdomain, the peptide interacted with the E289 and R293 side chains from the extended alpha helix. Remarkably, binding of C3P-pd to MSN resulted in a 2.3 Å shift of the  $\beta 5$ – $\beta 7$  beta-sheet from the alpha helix in the F3 lobe, when compared to our MSN structure that lacked any ligands. This caused the subdomain to adopt an “open” conformation similar to that observed in the MSN–CD44 structure. This is surprising, since C3P-pd does not contact the beta-sheet, suggesting an allosteric effect on the CD44 binding pocket.

Attempts to cocrystallize C3S1-pd and MSN were only successful in the presence of C3P-pd. The ternary complex structure, solved to 1.52 Å, contained both peptides bound, with C3S1-pd situated within the CD44 binding pocket (Figs. 3E and S4B) (Table S1). C3S1-pd, like CD44, forms a beta strand within the F3 lobe that binds in an antiparallel fashion to the  $\beta 5$ – $\beta 7$  beta sheet, displacing it from the alpha helix by 2.4 Å (not shown). Unlike CD44, C3S1-pd exclusively forms hydrogen bonds with the beta-sheet (Fig. 3F). Although in close proximity, the C3P-pd and C3S1-pd peptides do not contact each other. The structure also contained a third bound peptide (not shown) on the 2-fold axis between copies of the asymmetric unit. This peptide is likely to have been either C3P-pd or C3S1-pd, but we were unable to identify it due to poor side chain density, so it was modeled as penta-alanylglycine.

We further characterized the phage-display peptides for their ability to displace CD44 in the TR-FRET assay. C3S1-pd effectively competed with CD44, demonstrating an  $IC_{50}$  of around 220 nM (Fig. 3, H and K). In contrast, C3P-pd could only compete at high concentrations ( $IC_{50} = 1.4 \mu M$ ). This is not surprising, since C3P-pd was identified from selections carried out in the presence of the CD44 peptide. In addition, C3P-pd would not be predicted to sterically hinder CD44 when comparing superimposed structures of C3P-pd and CD44-bound MSN (Fig. 3F). TR-FRET assays were also developed using Cy5-conjugated phage display peptides (Fig. 3, I and J). Interestingly, CD44 was effective at displacing C3P-pd ( $IC_{50} = 9.4$  nM), suggesting inhibition through an allosteric mechanism. Surprisingly, C3S1-pd increased the FRET signal generated from MSN and C3P-pd-Cy5, showing an  $EC_{50}$  of around 130 nM. This suggests that C3S1-pd can allosterically stimulate binding of C3P-pd. However, the converse was not true, as C3P-pd had little effect on C3S1 binding (Fig. 3, J and K). Binding properties of the phage display peptides were measured by isothermal titration calorimetry (ITC). Both peptides bound to MSN in a 1:1 ratio, with C3P-pd and C3S1-pd having dissociation constants ( $K_D$ ) of around 260 and 45 nM, respectively (Figs. 3L and S5).

### uHTS screening for MSN–CD44 PPI inhibitors

We miniaturized and optimized the MSN–CD44 TR-FRET assay into a 1536-well ultrahigh-throughput screening (uHTS)

format to conduct screening against a chemical diversity compound library with the goal of obtaining small molecule inhibitors capable of disrupting the MSN–CD44 interaction. Details of assay optimization, miniaturization and screening will be published separately as an assay development and screening technical resource for scientific community. A chemical library composed of 138,000 compounds was screened, giving a primary hit rate of 0.2% (Fig. 4A). After removing known pan-assay interference compounds (23) from the primary list, we cherry-picked the remaining hits from the library stock and confirmed their activity through dose response in the TR-FRET assay. The compounds were then reordered and confirmed once more by TR-FRET dose response before being evaluated in an orthogonal chromatography-based glutathione-S-transferase (GST) pull-down assay using cell lysates with overexpressed full-length GST-MSN and Venus-Flag-CD44 (Fig. 4B). Hits confirmed in both assays were then assessed for binding to MSN by biophysical methods (see below). Out of 271 primary hits, two compounds with related chemical scaffolds (Fig. 4C) were selected to be evaluated further.


In the primary TR-FRET PPI assay, compounds 1 and 2 showed inhibitory values in the 5 to 20  $\mu M$  range (Fig. 4D). Compound 2 exhibited a relatively steep hill slope, which may indicate multiple binding events. The orthogonal GST pull-down assay confirmed that they were also active against full-length proteins in cell lysates (Fig. 4E). Orthogonal biophysical assays were then performed on the compounds to confirm their activity. Both compounds could bind MSN in a thermal shift assay, stabilizing the protein by 1 to 2 °C (Fig. 4F). Moreover, surface plasmon resonance experiments showed that binding of 1 and 2 to MSN could be fitted to a 1:1 model, with 4.2 and 0.7  $\mu M$   $K_D$  values, respectively (Fig. 4G).

To determine whether the identified compounds could interfere with MSN binding to CD44 in live cells, we established a split luciferase (NanoBiT) bioluminescence assay (Fig. 4H, left panel). MSN was fused to the large BiT at the N terminus, while CD44 was fused to the small BiT at the C terminus, with a constitutively active form of MSN (T588D) used to improve luminescence. Compounds 1 and 2 were found to be potent inhibitors of CD44–MSN interaction in live cells, with  $IC_{50}$  values of approximately 600 and 200 nM, respectively (Fig. 4H, right panel). Cocrystallization attempts of compound 1 and 2 with MSN were unsuccessful, likely because the compounds have low solubility in aqueous buffers (Fig. 4H).

### Structure-activity relationship studies with primary MSN–CD44 PPI hits

In order to improve the potency, selectivity, and solubility of compounds 1 and 2, we conducted structure–activity relationship (SAR) studies using compounds that we synthesized

CD44, green triangle). K,  $IC_{50}$  values derived from (H–J). Asterisk denotes stimulatory rather than inhibitory values. L, binding properties of MSN associated to C3P-pd and C3S1-pd peptides were measured by ITC. See Fig. S3 for thermograms and corresponding fitted curves.  $\Delta H$ , enthalpy; FERM, four-point-one ezrin radixin moesin; ITC, isothermal titration calorimetry;  $K_D$ , dissociation constant; MSN, moesin; N, stoichiometry; PPI, protein–protein interaction; TR-FRET, time-resolved FRET.



**Figure 4.** uHTS of a 138k compound library identifies MSN-CD44 small-molecule PPI inhibitors. **A**, scatter plot showing percentage inhibition with 138,214 compound library in the MSN-CD44 TR-FRET assay. Primary hit rate is 0.2%, with 271 compounds giving >50% inhibition. **B**, screening flow chart showing hit-to-lead identification strategy. **C**, structures of lead compounds based upon different chemical scaffolds. **D**, confirmatory TR-FRET dose-response curves of compound 1 ( $\text{IC}_{50} = 8.1 \pm 0.8 \mu\text{M}$ ;  $h = 1.7$ ) and compound 2 ( $\text{IC}_{50} = 18.2 \pm 1.5 \mu\text{M}$ ;  $h = 15.8$ ). **E**, dose response of compounds in GST pull-down assay. Cell lysates were obtained from cells transfected with full-length constructs of GST-tagged MSN and Flag-tagged CD44 and were incubated



## Discovery of MSN–CD44 interaction inhibitors for AD

in-house. We tested the derivatives in the MSN–CD44 TR-FRET assay and also utilized a TR-FRET counter screen employing identical FRET pairs in an unrelated PPI (SYK-ITAM) to eliminate false hits that interfere with the assay or are protein aggregators. We synthesized 17 derivatives of compound 1 while retaining the 2-phenylbenzothiazole core (Table S2), but most of the benzothiazole derivatives either registered strongly in the TR-FRET counter-screen or exhibited no activity. Therefore, we decided to focus on compound 2 SAR. We synthesized twelve derivatives of compound 2, all retaining the N-(4-(benzimidazole-2-yl)phenyl)acetamide core (Table S3). Of these, the 2,4-methoxybenzamide (2a) and the 3-chlorobenzamide (2b) substituents exhibited an approximately 2-fold increase in potency, while displaying no activity in the counter screen (Fig. 5A). Furthermore, both compounds 2a and 2b showed improved solubility in PBS buffer when compared to compound 2. Further testing demonstrated that compounds 2a and 2b were able to inhibit the MSN–CD44 interaction in cell lysates (Fig. 5B). Additionally, both compounds could stabilize MSN by 1 to 2 °C in thermal shift assays at low-micromolar concentrations (Fig. 5C).

### Discussion


Proteomic data from postmortem frontal cortex samples in AD cases and controls have been used in network modeling to identify two proteins, MSN and CD44, which are coregulated and linked to disease progression, including cognitive and pathological features (7). Although the impact of elevated levels of these proteins in AD brains is uncertain, inhibiting their function in microglia may reduce inflammation and prevent neuronal damage. Since CD44 is known to bind to the FERM domain of MSN, small molecule inhibitors that prevent this protein–protein interaction could potentially be useful tools for testing this hypothesis. Since MSN, along with other ERM proteins, is involved in critical cellular processes like cell adhesion, migration, and signaling (13), inhibiting a specific PPI with CD44 may be better tolerated by cells and impact only a portion of its functions. Although FERM domain proteins are known to be involved in various diseases, including cancer, cardiovascular, neurological, and immunological disorders (24–26), there is currently limited knowledge on the feasibility of developing small-molecule modulators that can target these proteins for therapeutic interventions. In one study, screening of the ERM protein ezrin against a compound library identified binders that inhibited formation of a phosphorylated active form of the protein (27), although the mechanism by which they blocked phosphorylation is not

clear. In this work, we show that the FERM domain is a tractable target. Small molecule inhibitors with moderate potency were identified that could prevent the association of the FERM domain of MSN to the receptor tail of the CD44. Furthermore, by using phage display, peptide binders were found that could modify the association of MSN with CD44 *via* an allosteric mechanism, highlighting other locations for compound binding that impact the functionality of the FERM domain.

Structural studies on the MSN FERM domain (this work and (22)) show that ERM proteins can adopt either an “open” or “closed” conformation, the open form of which is permissive for binding of receptor tails, independent from the inhibitory C-terminal tail. Comparison of our peptide bound and ligand free MSN FERM domain structures show that the  $\beta 5$ – $\beta 7$  beta-sheet with the F3 lobe is displaced from the extended alpha helix by 2 Å in order to accommodate the C-terminal tail of CD44. Through binding to MSN, CD44 makes extensive contacts to the beta-sheet, forming an antiparallel beta strand. Mutagenesis and structural data point to CD44 making hydrophobic contacts with most exposed hydrophobic residues within the binding pocket. In addition, CD44 makes contact with the extended alpha helix. In particular, interaction of H288 within the helix with the peptide backbone was critical for CD44 interaction. We propose that small molecules that bind either to the hydrophobic pocket within MSN or interact with H288 may interfere with CD44 binding.

During the phage display screening for allosteric pockets on the MSN FERM domain, we identified a peptide (C3P-pd) that binds to a cleft situated between the F1 and F3 subdomains, close to the suggested PIP<sub>2</sub>-binding site. The binding of the peptide caused the F3 lobe to assume an “open” conformation permissive to receptor binding. A previous study by Hamada *et al.* (17) (2000) reported a similar “open” structure of radixin when it was cocrystallized with IP<sub>3</sub>, the head group of PIP<sub>2</sub>. This led to the proposal that PIP<sub>2</sub> binding to full-length ERM proteins helps to displace the inhibitory C-terminal domain through a shift of the beta-sheet in the F3 lobe. However, a later study found that PIP<sub>2</sub> is required for the binding of MSN to the C-terminal tails of receptors, even when the C-terminal domain is disengaged through the use of the T558D phosphomimetic mutation (28). Thus, we suggest that PIP<sub>2</sub> may induce the F3 subdomain to adopt an “open” state, which can enhance receptor binding in addition to or instead of helping to disengage the C-terminal domain. However, it is important to note that C3P-pd may not stimulate binding within the F3 subdomain in the same way as PIP<sub>2</sub>. C3P-pd did not enhance CD44 binding and actually inhibited binding of a second phage

with the compounds. Immunoblotting was performed to detect GST and Flag. Presented are representative immunoblots among replicates, demonstrating that compounds 1 and 2 induce the dissociation of CD44 from MSN. *F*, thermal shift assay, showing melting temperature ( $T_m$ ) curves of MSN with compounds. The average change in  $T_m$  (av.  $\Delta T_m$ ), compared to DMSO alone, was determined from two experiments (1: 1.1 °C at 20  $\mu$ M; 2: 1.9 °C at 20  $\mu$ M). *G*, dose response of compound binding to MSN FERM domain, measured by SPR.  $K_D$  measurements were determined for compounds 1 (4.2  $\mu$ M) and 2 (0.7  $\mu$ M). RU = response units. *H*, dose response of compounds in cell-based NanoBIT bioluminescence assay, with HEK293 cells expressing LgBIT-MSN(T588D) and SmBit-CD44 fusions. Luminescence from reconstituted split luciferase was measured after substrate addition. Activities were determined from two independent experiments (1: 0.57  $\pm$  0.17 and 0.69  $\pm$  0.12  $\mu$ M; 2: 0.18  $\pm$  0.04 and 0.19  $\pm$  0.06  $\mu$ M). *I*, solubility of compounds (PBS buffer, 1% DMSO), as measured by nephelometry. DMSO, dimethyl sulfoxide; FERM, four-point-one ezrin radixin moesin; GST, glutathione-S-transferase; LgBIT, large binary technology; MSN, moesin; PPI, protein–protein interaction; RNU, relative nephelometric unit; SmBit, small binary technology; TR-FRET, time-resolved FRET; uHTS, ultrahigh-throughput screening.



**Figure 5. Compound 2 and analogs disrupt the MSN-CD44 PPI.** A, structures of compound 2 and analogs, with associated solubility data (PBS, 1% DMSO), and activity in both the MSN-CD44 TR-FRET assay and an unrelated PPI (SYK-FCER1G) TR-FRET assay. The *bottom panel* shows the MSN-CD44 TR-FRET dose response for compound 2a ( $h = 2.4$ ) and compound 2b ( $h = 2.3$ ). Solubility was measured by nephelometry. B, Dose response of compounds in GST pull-down assay. Cell lysates were obtained from cells transfected with full-length constructs of GST-tagged MSN and Flag-tagged CD44 and were incubated with the compounds. Immunoblotting was performed to detect GST and Flag, and a representative immunoblot from two experiments is shown. C, thermal shift assay, showing representative melting temperature ( $T_m$ ) curves of MSN with compounds. The average change in  $T_m$  (av.  $\Delta T_m$ ), compared to DMSO alone, was determined from two experiments (2a: 1.3 °C at 50 μM; 2b: 1.2 °C at 50 μM). DMSO, dimethyl sulfoxide; GST, glutathione-S-transferase; MSN, moesin; PPI, protein-protein interaction; TR-FRET, time-resolved FRET.

display peptide (C3S1-pd) that bound similarly to CD44. Interestingly, C3P-pd binding was stimulated by C3S1-pd, suggesting that the allosteric modulation works in both directions. It is conceivable that receptor tail binding at the membrane may stimulate PIP<sub>2</sub> binding as well. In summary, our findings demonstrate that ligand binding in the F1-F3 cleft can alter receptor tail binding. The discovery of C3P-pd could potentially lead to the development of peptidomimetics that allosterically regulate CD44 binding to ERM proteins. It would be valuable to investigate if C3P-pd can compete with PIP<sub>2</sub> for MSN binding, and if this is the case, designing peptidomimetics based on C3P-pd could block PIP<sub>2</sub> binding to ERM proteins.

Our study aimed to identify small molecule inhibitors of the MSN-CD44 interaction. High-throughput screening of a large chemical library revealed two hit series with distinct chemotypes. Both hits successfully displaced CD44 from MSN, with IC<sub>50</sub> values in the low-micromolar range, in both experiments with purified proteins and cell lysates. Moreover, the compounds exhibited potency in live cells. It remains unclear why these compounds show greater effectiveness in a cellular environment than when used with isolated proteins and peptides. One possible explanation is that the use of full-length protein in the context of membrane association enhances compound potency. Alternatively, the compounds may undergo metabolic activation within the cell. We cannot exclude

## Discovery of MSN–CD44 interaction inhibitors for AD

off-target effects for the observed increase in activity in cells. We attempted to perform initial SAR on the thiazole hit but failed to obtain significant improvements in activity. Nevertheless, we made progress with the benzimidazole hits by enhancing potency while minimizing activity in a counter screen. Although compound solubility in aqueous buffers of this series remains a challenge, our SAR experiments indicated that increased solubility does not necessarily go hand-in-hand with decreased potency. We are currently evaluating the potential of these hits to alleviate microglial hyperactivity in tissue culture assays.

In summary, our findings provide a solid foundation for future medicinal chemistry efforts targeting ERM proteins for AD therapy. We have demonstrated that FERM proteins are a feasible target for the development of protein–protein interaction inhibitors. However, further optimization of the lead compounds is necessary to improve their potency and physicochemical properties as well as to evaluate their suitability for use in cellular assays.

### Experimental procedures

#### DNA constructs

Expression plasmid constructs used in protein purification were generated by PCR amplification of the FERM domain of human MSN (residues 1–345) from the Mammalian Gene Collection cDNA library (IMAGE:4908580). The PCR product was cloned into the *Escherichia coli* expression vector pNIC28-Bsa4 using ligation-independent cloning, giving rise to an N-terminal fusion with a 6His tag and a TEV protease cleavage site (MSNA-c001). Constructs for purification of MSN-H288A (MSNA-c028), MSN-L281R (MSNA-c025), and the MSN-H288A, MSN-L281R (MSNA-c033) were produced by site-directed mutagenesis, using the KLD enzyme kit (NEB, M0554S). Full-length Venus-Flag-tagged CD44 and GST-tagged MSN for mammalian expression were generated using Gateway® cloning kit (Invitrogen). Source DNA for CD44 cloning was obtained from the ORFeome library (29). The vector backbones are pDEST27 vector (Invitrogen) for GST-tagged MSN and lab customized pFUW for Venus-Flag-tagged CD44. For NanoBiT split luciferase assay, BiBiT Flexi vectors were custom ordered from Promega.

#### Protein purification

WT and mutant MSN were produced using *E. coli* BL21(DE3)-R3-pRARE cells grown in terrific broth. Prior to harvesting, cells were shifted to 18 °C for 16 h after IPTG induction. Cells were lysed by sonication in lysis buffer containing 50 mM Hepes (pH 7.5), 500 mM NaCl, 10 mM imidazole, 5% glycerol, 1 mM tris(2-carboxyethyl)phosphine (TCEP). MSN protein was bound to equilibrated Ni-iminodiacetic acid resin for 1 h before two batch washes in lysis buffer. Beads were subsequently loaded onto a drip column, followed by washing with lysis buffer containing 30 mM imidazole, before finally eluting bound protein with lysis buffer containing 300 mM imidazole. For protein crystallography, the 6His tag was cleaved off by the addition of a 1:10 mass ratio of

6His-TEV protease while undergoing dialysis (10k molecular weight cut-off) in lysis buffer lacking imidazole for 16 h at 4 °C. TEV protease and the cleaved 6His tag was subsequently removed with Ni-iminodiacetic acid resin equilibrated in lysis buffer. For TR-FRET assays, the N-terminal tag was left intact. Both tagged and untagged forms of MSN were further purified by size-exclusion chromatography in lysis buffer lacking imidazole. The molecular mass of purified proteins was confirmed by intact mass spectrometry.

#### Crystallization and data collection

Crystals of the FERM domain of either WT or H288A mutant MSN (1–345) were obtained by first incubating protein with a 21-residue CD44 peptide (672-SRRRCGQKKKLVINSNGNGAVEDY-693) at a 1:1.1 ratio (final 12–14 mg/ml protein concentration) for 30 min on ice. WT and H288A mutant proteins were crystallized at 4 °C in sitting drops by addition of reservoir (0.1–0.2 M ammonium acetate, 32–34% 2-propanol, 0.1 M Tris pH 8.5) in 1:2 or 2:1 ratios, respectively. Although the CD44 peptide was necessary for crystallization of these proteins, the peptide was not visible in structures obtained. The MSN-L281R mutant was crystallized in sitting drops containing a 1:2 ratio of protein to reservoir (20% PEG3350, 0.2 M NaF, 10% ethylene glycol, 0.1 M bis-tris-propane pH 8.5) at 4 °C. Crystals of MSN (1–345) with bound CD44 were obtained by first incubating MSN with a minimal 8-residue CD44 peptide (678-QKKKLVIN-685) at a 1:5 ratio (final 16 mg/ml protein) for 30 min on ice, followed by incubation in drops containing a 1:1 ratio of protein-peptide mix to reservoir (20% PEG3350, 0.2 M potassium thiocyanate, 10% ethylene glycol, 0.1 M bis-tris-propane pH 6.5) at 4 °C. Crystals of MSN (1–345) with bound phage display peptide C3P-pd were obtained by incubating MSN with peptide (EDGGSWKYPDAFELSG) at a 1:2 ratio (final 18 mg/ml protein) for 30 min on ice, followed by incubating drops containing a 1:2 ratio of protein-peptide mix to reservoir (20% PEG3350 10% ethylene glycol, 0.2 M NaBr, 0.1 M bis-tris-propane pH 7.5) at 4 °C. Crystals of MSN (1–345) bound to both phage display peptides C3P-pd and C3S1-pd (EDGSSWEYIWTLPSPG) were obtained by incubating protein and peptides in a 1:2:2 ratio (final 16 mg/ml protein) for 30 min on ice, followed by incubating drops containing a 2:1 ratio of protein-peptide mix to reservoir (25% PEG4000, 0.2 M ammonium sulfate, 0.1 M acetate pH 4.5) at 4 °C. All crystals were grown in 150 nl sitting drops. Most crystals were cryoprotected by the addition of 1 µl of reservoir solution immediately before harvesting. For crystals grown in 2-propanol, 1 µl of 25% PEG 3350 was used.

Data were collected at Diamond Light Source beamlines I03 and I04 and indexed integrated with Dials (30). Data with low anisotropy (6TXQ, 6TXS, 8CIR) were scaled with Aimless (31), while data with significant anisotropy were scaled with STARANISO (32) and Aimless. The anisotropic high-resolution cut-offs were as follows: 8CIS: 2.12 to 1.42 Å, 8CIT: 3.97 to 2.54 Å, 8CIU: 3.24 to 2.39 Å. The Apo structure was determined first by molecular replacement performed by

Phaser (33) using 1E5W as a model (22). The apo structure was used in molecular replacement to determine the remaining structures. The two mutant structures were refined with successive rounds of Coot (34) and Buster (35), while the other structures were refined with Coot and Refmac5 (36). Waters were initially modeled in the L281R structure (8CIT) and did cause a decrease in R-factors, but the majority refined to abnormally low B-factors that are assumed to have been a result of noisy, anisotropic data with low completeness at a resolution required to see waters. It was decided that all waters would be removed for the deposition. The final models were verified with MolProbity (37) and deposited in the PDB under the accession codes shown in Table S1. Movement of FERM subdomains was analyzed by DynDom, available at <https://dyndom.cmp.uea.ac.uk/dyndom/main.jsp> (38).

### TR-FRET assay

MSN TR-FRET experiments were performed in 20  $\mu$ l reactions, using 384-well shallow-well microplates. Final reaction components contained 6His-MSN (2 nM), FITC-conjugated CD44 peptide (8 nM; SRRRCGQKKLVNSGNGAVEDYK-FITC), Tb-conjugated anti-6His antibody (53 ng/ml; Cisbio) in assay buffer containing 25 mM Hepes (pH 7.5), 200 mM NaCl, 0.1% bovine serum albumin, and 0.05% Tween-20. After a 2 h incubation (at RT), TR-FRET signals were measured on a BMG Labtech PHERAstar FSX reader using a Lanthascreen Optics Module. A 200- $\mu$ s delay was used after excitation with a flash lamp before measurement of fluorescence emission at 490 and 520 nm. TR-FRET ratios of fluorescent intensity at 520 nm to 490 nm were calculated. The  $IC_{50}$  was determined by fitting a four parametric logistic curve to the data.

### Phage display screening

MSN was screened against an unbiased, random 10-mer peptide phage display library utilizing the pIII coat protein of filamentous M13 phage, as previously described with modification (39, 40). Briefly, His-bind magnetic Dynabeads (Invitrogen) were washed with Tris-buffered saline-containing 0.05% Tween-20 (TBS-T) and then incubated with either 50  $\mu$ l of 3.2  $\mu$ M 6His-MSN in TBS-T or buffer alone for 30 min at RT with rotation. All selections were carried out in low-retention microfuge tubes. The beads were washed and blocked three times with casein blocking buffer (CBB; 1% Hammarsten-grade casein in TBS, pH 7.4), and MSN-beads were incubated for 30 min at RT with or without of 1  $\mu$ M CD44 competitor peptide. The phage library, diluted in CBB, was added to give  $5 \times 10^{11}$  phage molecules. Selections were incubated for 2 h at 4 °C with rotation, followed by four washes with TBS-T. Bound phage were eluted with 100  $\mu$ l of 0.2 M glycine (pH 2.5) for 8 min at 37 °C, followed by immediate neutralization with the addition of 10  $\mu$ l of 1 M Tris (pH 11). Phage selections were amplified by adding them to 1 ml TG1 cells (Lucigen) grown to midlog phase ( $A_{600} \sim 0.6$ ) and incubated at 37 °C for 1.5 h. Subsequently, cells were diluted 1:50 into 30 ml 2xYT media containing 15  $\mu$ g/ml tetracycline and grown overnight at 37 °C. At the same time,

phage were titered using TG1 cells and tetracycline agar plates. The following day, phage were precipitated with 5X PEG 8000-NaCl (20% PEG/2.5 M NaCl) and pelleted phage were washed with and resuspended into TBS. Selections were repeated three times with input phage dropped 5-fold for each round, resulting in enrichment (>10,000-fold) over control selections with only beads. Phage isolated from individual colonies were screened for MSN binding using ELISA. Briefly, 0.5  $\mu$ g MSN in PBS was adsorbed to a 384-well white Nunc MaxiSorp plate overnight at 4 °C. Phage were serially diluted 3-fold in CBB and added to coated wells. The plate was incubated for 1.5 h at RT, and unbound phage were removed by washing three times with TBS-T. A 1:10,000 dilution of anti-M13 antibody-horseradish peroxidase (HRP) conjugate in CBB was added to each well and incubated for 1 h at RT. Wells were washed three times with TBS-T and phage binding was detected by addition of 20  $\mu$ l SuperSignal ELISA Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and read on an Envision multilabel plate reader (PerkinElmer). Phage ELISA binding curves were analyzed using a four-parameter nonlinear curve fit to determine phage  $EC_{50}$ .

### Ultrahigh-throughput screening

uHTS for small molecule PPI inhibitors of MSN–CD44 interaction was performed using the TR-FRET assay miniaturized into the 1536-well format. Briefly, the optimized reaction mixture (1.5 nM of 6His-MSN and 25 nM of FITC-CD44 peptide in the presence of anti-His-Tb at final 1:1000 dilution) was dispensed at 5  $\mu$ l per well into 1536-well black plates (Corning Costar, #3724). A pin tool integrated with the Biomek NX automated liquid handling workstation (Beckman Coulter) was used to add 0.1  $\mu$ l of library compound dissolved in dimethyl sulfoxide (DMSO). Final compound and DMSO concentrations were 20  $\mu$ M and 2%, respectively. The plates were centrifuged at 1000 rpm for 5 min and incubated at RT for 2 h. TR-FRET signals were then measured using the BMG Labtech PHERAstar FSX reader with the homogenous time resolved fluorescence optic module (excitation at 337 nm; emission A at 490 nm; emission B at 520 nm). TR-FRET ratios of fluorescent intensity at 520 nm to 490 nm were calculated.

Screening data were analyzed using Bioassay software from CambridgeSoft (<https://cambridgesoft-bioassay.software.informer.com/11.0/>). The signal-to-background (S/B) ratio and  $Z'$  for each screening plate were calculated using the following equations:  $S/B = F_{\text{control}}/F_{\text{blank}}$ ,  $Z' = 1 - [(3 \cdot SD_{\text{control}} + 3 \cdot SD_{\text{blank}})/(F_{\text{control}} - F_{\text{blank}})]$ . The inhibitory effect of compounds on the TR-FRET signal was expressed as a percentage of control, and calculated on a plate-by-plate basis, as follows: % of inhibition =  $100 - [(F_{\text{compound}} - F_{\text{blank}})/(F_{\text{control}} - F_{\text{blank}}) \cdot 100]$ , where  $F_{\text{compound}}$  is the TR-FRET signal from compound wells,  $F_{\text{control}}$  is the average TR-FRET signal from DMSO control wells, which defines the highest signal, and  $F_{\text{blank}}$  is the average signal from MSN and anti-His-Tb only wells, lacking the FITC peptide. Compounds where percentage inhibition was greater than 50 were defined as primary hits. The S/B across all screening plates was greater than ten, and

## Discovery of MSN–CD44 interaction inhibitors for AD

the  $Z'$  greater than 0.5. A chemical diversity library containing 138,214 compounds (ChemDiv and Asinex) was screened. After cherry-picking the hits from the library stock and confirming their activity through dose response in the TR-FRET assay, the primary hits were repurchased for further confirmation by dose response in the TR-FRET assay.

### GST pull-down assay

TR-FRET–confirmed hits were validated in a GST pull-down assay using cell lysates of HEK293 cells coexpressing full-length constructs of both Venus-Flag–tagged CD44 and GST-tagged MSN. The Venus tag was used as a marker for CD44 protein expression. Dose responses were performed by the addition of 0.5  $\mu$ l of compounds (in DMSO) to 100  $\mu$ l of cell lysates, which were diluted in 0.25% Triton lysis buffer (150 mM NaCl, 10 mM Hepes, pH 7.5, 0.25% Triton X-100, phosphatase inhibitor (Sigma, P5726), and protease inhibitor cocktail (Sigma, P8340)). The mixtures were rotated for 1 h at 4 °C before the addition of 15  $\mu$ l of 50% pre-equilibrated GST resin. After incubation on a rotator for 1.5 h at 4 °C, the GST resin was washed three times with 1 ml of 0.25% Triton lysis buffer. SDS sample buffer was added prior to boiling for 5 min. Samples were analysed by SDS-PAGE and immunoblotting, using anti-FLAG antibody for CD44 (1:1000 dilution of anti-Flag M2-HRP antibody; Sigma, A8592) and anti-GST antibody for GST-MSN (1:1000 dilution of anti-GST (2.6H1) Mouse mAb; Cell Signaling, 2624S). For GST detection, a secondary HRP-conjugated antibody was used (1:5000 dilution of AffiniPure Goat Anti-Mouse IgG (H + L); Jackson Immuno Research, 115-035-003).

### Thermal shift assay

Compounds in DMSO were diluted 1 in 50 in assay buffer (25 mM Tris pH 8.0, 150 mM NaCl, 5% glycerol) containing 2  $\mu$ M MSN. After removal of compound precipitates by centrifugation, the mixture was incubated for 30 min at RT. Sypro Orange (Thermo Fisher Scientific S6650) was then added at 20 $\times$  concentration. Melting curves were obtained on a qPCR machine (Eppendorf RealPlex 4), ramping up from 25 to 95 °C, at 1 °C min<sup>-1</sup>. To calculate the  $T_m$ , data was fitted to the Boltzmann equation using Prism GraphPad (<https://www.graphpad.com/>).

### Surface plasmon resonance assay

Binding experiments were performed using a Biacore X100 instrument with a carboxymethylated dextran (CM5) sensor chip. Protein ligand was bound to the sensor surface by amine coupling in acetate buffer pH 4, giving 4000 response units. The protein-bound sensor was equilibrated in running buffer (20 mM Hepes pH 7.5, 200 mM NaCl, 1 mM TCEP, 0.005% Tween-20) prior to compound injection. Multicycle kinetic analysis was performed with compounds (0.5–8  $\mu$ M). Data were fitted with the Biacore evaluation software, using a 1:1 binding model.

### Isothermal titration calorimetry

ITC was performed to quantify the thermodynamics of binding between MSN and the synthetic phage display

peptides. MSN was buffer exchanged (NAP-5 column; GE Healthcare Life Sciences) and diluted to 20  $\mu$ M in ITC buffer (50 mM Hepes, pH 7.4, 200 mM NaCl, and 0.5 mM TCEP). Phage display peptides C3P-pd and C3S1-pd were diluted to 200  $\mu$ M in ITC buffer. Protein and peptide concentrations were calculated by measuring their absorption at 280 nm and using their expected extinction coefficients, calculated by Protparam (<https://web.expasy.org/protparam/>). ITC measurements were recorded at 25 °C using an AutoITC 200 microcalorimeter (Malvern Instruments). Injections of 0.2  $\mu$ l peptide were titrated into 200  $\mu$ l MSN at 180s intervals with a reference power of 7  $\mu$ cal/sec. Estimated heats of dilution were subtracted and titration data analyzed using Microcal LLD Origin7 software by nonlinear least squares and fitting a one-site model as a function of the peptide:protein ratio.

### NanoBit split luciferase assay in live cells


The HEK293T (American Tissue Type Collection, CRL-3216) cells were grown in Dulbecco's modified Eagle's medium (Corning, 10-013-CV) supplemented with 10% fetal bovine serum (Sigma, F0926-500 ml), 100 U/ml penicillin, and 100  $\mu$ g/ml streptomycin (Sigma, P0781-100 ml) at 5% CO<sub>2</sub> and 37°C in a humid environment. Four BiBit Flexi vectors for each of the full-length CD44, MSN(T558D), and MSN(T558A) genes with either N-terminal or C-terminal small binary technology (SmBit) and large binary technology (LgBiT) fusions were produced using Flexi-based cloning (Promega). Best luminescence signals were obtained with CD44 containing a C-terminal smBiT fusion (C-terminal smBiT) and MSN(T558D) containing an N-terminal LgBiT fusion (C-terminal smBiT). LgBiT-MSN(T558A) was used as negative control. To evaluate the effects of the compounds, 30  $\mu$ l of HEK293T cell suspension was seeded at 6000 cells/well in a 384-well plate (Corning, 3826). The next day, a mixture of 20 ng of CD44-smBiT and 5 ng of LgBiT-MSN(T558D) plasmids was added to 75 ng of Eugene HD (Promega, Cat#2312) transfection reagent diluted in Dulbecco's modified Eagle's medium, and 10  $\mu$ l of the mixture was added to each well. After 18 h, the cells were treated with a 2-fold serial dilution of compounds (6.25–0.098  $\mu$ M) that was dissolved in DMSO and then incubated for 3 h. Next, 10  $\mu$ l of Nano-Glo Live-Cell Reagent (Promega, N2014) was added to the wells, and the plates were incubated for 20 min at 37 °C. The signal was then measured using the 2102 Envision Multilabel Reader (PerkinElmer).

### Synthesis details for selected compounds

Synthesis of compounds 1 (Figure 6) and 2, including analogs 2a and 2b (Figure 7), are detailed below. Compound identity and purity were confirmed by NMR and LC-MS, shown in [Supplementary information](#).

*Preparation of 4-amino-N-(4-(6-(4-aminobenzamido)benzo[d]thiazol-2-yl)phenyl)benzamide bis(2,2,2-trifluoroacetate) (1)*

To a flask was added 4-((tert-butoxycarbonyl)amino)benzoic acid (236 mg, 2.4 equiv, 995  $\mu$ mol) and CH<sub>2</sub>Cl<sub>2</sub>, followed



**Figure 6. Synthesis of compound 1.** a, 4-((*tert*-butoxycarbonyl)amino)benzoic acid,  $\text{CH}_2\text{Cl}_2$ ,  $\text{SOCl}_2$ , 0 to 40 °C; (b) *tert*-butyl (4-(chlorocarbonyl)phenyl) carbamate, diisopropylethylamine, tetrahydrofolic acid, 65 °C; and (c) TFA,  $\text{CH}_2\text{Cl}_2$ .

by addition of thionyl chloride (103  $\mu\text{l}$ , 3.4 equiv, 1.40 mmol) at 0 °C. The reaction was allowed to warm to rt and then stirred at 40 °C for 4 h. The reaction was concentrated *in vacuo* to yield a yellow solid. To this was added 2-(4-aminophenyl)benzo[*d*]thiazol-6-amine (100 mg, 1.0 equiv, 414  $\mu\text{mol}$ ) and diisopropylethylamine (DIPEA; 217  $\mu\text{l}$ , 3.0 equiv, 1.24 mmol) in tetrahydrofolic acid (THF; 1.66 ml, 0.25 M) and the reaction was stirred at 65 °C. After 1 h a precipitate crashed out of solution. The reaction was cooled and diluted with  $\text{H}_2\text{O}$  and the precipitate was collected *via* vacuum filtration. The product was further purified by washing with  $\text{CH}_2\text{Cl}_2$  under vacuum to yield the desired product *tert*-butyl (4-((2-(4-(4-((*tert*-butoxycarbonyl)amino)benzamido)phenyl)benzo[*d*]thiazol-6-yl)carbamoyl)phenyl)carbamate as a white solid, which was used without further purification. *Tert*-butyl (4-((2-(4-(4-((*tert*-butoxycarbonyl)amino)benzamido)phenyl)benzo[*d*]thiazol-6-yl)carbamoyl)phenyl)carbamate was added to a vial with  $\text{CH}_2\text{Cl}_2$  and TFA (1:1) and the reaction stirred at RT for 1 h. The reaction was concentrated *in vacuo* to yield the desired product 4-amino-*N*-(4-(6-(4-aminobenzamido)benzo[*d*]thiazol-2-yl)phenyl)benzamide bis(2,2,2-trifluoroacetate) as a yellow amorphous solid (28 mg, 10% over two steps).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  10.07 (d,  $J$  = 12.1 Hz, 2H), 8.62 (d,  $J$  = 2.0 Hz, 1H), 8.06 to 7.92 (m, 5H), 7.78 (dd,  $J$  = 8.7, 1.8 Hz, 5H), 6.71 to 6.65 (m, 4H). HPLC purity: >95%; LCMS: calculated for  $\text{C}_{27}\text{H}_{22}\text{N}_5\text{O}_2\text{S}$  [ $\text{M} + \text{H}$ ] $^+$ : 480.15. Found: 480.09.


Preparation of *N*-(4-(1*H*-benzo[*d*]imidazol-2-yl)phenyl)-2-methoxybenzamide (2)

A solution of 4-(1*H*-benzo[*d*]imidazol-2-yl)aniline hydrochloride (0.200 g, 1.0 equiv, 0.810 mmol) in THF (3.0 ml) at

0 °C was treated with DIPEA (0.280 ml, 2.0 equiv, 1.60 mmol), followed by dropwise addition of 2-methoxybenzoyl chloride (0.150 ml, 1.2 equiv, 0.980 mmol) over 5 min. After 1 h at 0 °C, the reaction mixture was allowed to warm to RT and then was heated to 65 °C with stirring for 12 h. The product crashed out of solution and was collected *via* vacuum filtration using ethanol, followed by diethyl ether to collect the desired product *N*-(4-(1*H*-benzo[*d*]imidazol-2-yl)phenyl)-2-methoxybenzamide as an off-white amorphous solid (100 mg, 35%).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  10.61 (s, 1H), 8.37 (d,  $J$  = 9.0 Hz, 2H), 8.07 (d,  $J$  = 8.9 Hz, 2H), 7.83 (dd,  $J$  = 6.1, 3.2 Hz, 2H), 7.66 (dd,  $J$  = 7.6, 1.8 Hz, 1H), 7.59 to 7.49 (m, 3H), 7.22 (dd,  $J$  = 8.5, 0.9 Hz, 1H), 7.10 (td,  $J$  = 7.5, 1.0 Hz, 1H), 3.92 (s, 3H). HPLC purity: >95%; LCMS: calculated for  $\text{C}_{21}\text{H}_{18}\text{N}_3\text{O}_2$  [ $\text{M} + \text{H}$ ] $^+$ : 344.14. Found: 344.04.

Preparation of *N*-(4-(1*H*-benzo[*d*]imidazol-2-yl)phenyl)-2,4-dimethoxybenzamide (2a)

A solution of 4-(1*H*-benzo[*d*]imidazol-2-yl)aniline hydrochloride (0.200 g, 1.0 equiv, 0.810 mmol) in THF (3.0 ml) at 0 °C was treated with DIPEA (0.280 ml, 2.0 equiv, 1.60 mmol), followed by dropwise addition of 2,4-dimethoxybenzoyl chloride (0.200 g, 1.2 equiv, 0.980 mmol) over 5 min. After 1 h at 0 °C, the reaction mixture was allowed to warm to RT and then was heated to 65 °C for 12 h. The product crashed out of solution and was collected *via* vacuum filtration with ethanol, followed by diethyl ether to yield the desired product *N*-(4-(1*H*-benzo[*d*]imidazol-2-yl)phenyl)-2,4-dimethoxybenzamide as an off-white amorphous solid (150 mg, 48%).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  10.33 (s, 1H), 8.25 (d,  $J$  = 8.7 Hz, 2H), 8.07 (d,  $J$  = 8.7 Hz, 2H), 7.83 to 7.74 (m, 3H), 7.51 (dd,  $J$  = 6.3,



**Figure 7. Synthesis of compounds 2, 2a, and 2b.** a, acyl chloride, diisopropylethylamine, tetrahydrofolic acid, 0 to 65 °C.

## Discovery of MSN-CD44 interaction inhibitors for AD

3.1 Hz, 2H), 6.74 (d,  $J = 2.3$  Hz, 1H), 6.70 (dd,  $J = 8.7, 2.3$  Hz, 1H), 3.98 (s, 3H), 3.86 (s, 3H). HPLC purity: >95%; LCMS: calculated for  $C_{22}H_{20}N_3O_3$  [M + H]<sup>+</sup>: 374.15. Found: 374.37.

Preparation of *N*-(4-(1*H*-benzo[d]imidazol-2-yl)phenyl)-3-chlorobenzamide (2b)

A solution of 4-(1*H*-benzo[d]imidazol-2-yl)aniline hydrochloride (0.200 g, 1.0 equiv, 0.810 mmol) in THF (3 ml) at 0 °C was treated with DIPEA (0.280 ml, 2.0 equiv, 1.60 mmol), followed by dropwise addition of 3-chlorobenzoyl chloride (0.130 ml, 1.2 equiv, 0.980 mmol) over 5 min. After 1 h at 0 °C, the reaction mixture was allowed to warm to RT and further to 65 °C with stirring for 12 h. The mixture was allowed to cool to RT, and the solvent was removed *in vacuo*. The crude material was sonicated with water (2 ml), followed by addition of  $CH_2Cl_2$  (4 ml) for 5 min to give a solid. The solid was collected *via* vacuum filtration with diethyl ether to yield the desired product *N*-(4-(1*H*-benzo[d]imidazol-2-yl)phenyl)-3-chlorobenzamide as an off-white amorphous solid (83 mg, 29%). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 10.86 (s, 1H), 8.36 (d,  $J = 8.8$  Hz, 2H), 8.13 (d,  $J = 8.8$  Hz, 2H), 8.07 (t,  $J = 1.9$  Hz, 1H), 7.98 (dt,  $J = 7.8, 1.4$  Hz, 1H), 7.82 (dd,  $J = 6.1, 3.1$  Hz, 2H), 7.71 (ddd,  $J = 8.0, 2.2, 1.1$  Hz, 1H), 7.61 (t,  $J = 7.9$  Hz, 1H), 7.53 (dd,  $J = 6.1, 3.1$  Hz, 2H). HPLC purity: >95%; LCMS: calculated for  $C_{20}H_{15}ClN_3O$  [M + H]<sup>+</sup>: 348.09. Found: 347.99.

### Data availability

All data are contained within the article and [Supporting information](#).

**Supporting information**—This article contains supporting information.

**Acknowledgments**—We would like to thank all members of the Emory-Sage-SGC TREAT-AD center, the TREAT-AD advisory board members, and the NIA Scientific Officers, Lorenzo Refolo and Suzana Petanceska, for the advice and guidance on the study. We would also like to acknowledge Diamond Light Source for granting us beamtime (proposals mx19301 and mx28172) and the personnel at beamlines I03 and I04 for helping with crystal testing and data collection. We thank the CMD Biotechnology group for help with plasmid cloning, test expression, and mass spectrometry. The TREAT-AD Consortium was established by the National Institute on Aging (NIA). The Structural Genomics Consortium is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Genentech, Innovative Medicines Initiative (EU/EFPIA), Janssen, Merck KGaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.

**Author contributions**—Y. D., A. A. I., S. V. F., O. G., A. I. L., A. D. A., K. H. P., H. F., and V. L. K. conceptualization; Y. D., A. A. I., S. V. F., O. G., A. I. L., A. D. A., K. H. P., H. F., and V. L. K. methodology; Y. D., W. J. B., T. M. L., J. K. A.-G., K. Q., F. M. B., A. S., F. O. N., and V. L. K. investigation; Y. D., W. J. B., T. M. L., J. K. A.-G., K. Q., F. M.

B., A. S., F. O. N., and V. L. K. formal analysis; V. L. K. writing-original draft; Y. D., W. J. B., T. M. L., J. K. A.-G., K. Q., F. M. B., A. S., F. O. N., A. A. I., S. V. F., O. G., P. E. B., A. I. L., A. D. A., K. H. P., H. F., and V. L. K. writing-review and editing.

**Funding and additional information**—The research reported in this manuscript was led by the Emory-Sage-SGC TREAT-AD center and supported by grant U54AG065187 from the NIA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIA. The funders played no role in study design, data collection and analysis, decision to publish, or manuscript preparation.

**Conflict of interest**—The authors declare that they have no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: AD, Alzheimer's disease; CBB, casein blocking buffer; DIPEA, diisopropylethylamine; DMSO, dimethyl sulfoxide; ERM, ezrin radixin moesin; FREM, four-point-one ezrin radixin moesin; GST, glutathione-S-transferase; HRP, horseradish peroxidase; ITC, isothermal titration calorimetry; LgBiT, large binary technology; MSN, moesin; PIP<sub>2</sub>, phosphatidylinositol 4,5-bisphosphate; PPI, protein-protein interaction; SAR, structure-activity relationship; S/B, signal-to-background ratio; SmBiT, small binary technology; TBS, tris-buffered saline; TBS-T, TBS containing 0.05% Tween-20; TCEP, tris(2-carboxyethyl)phosphine; THF, tetrahydrofolic acid; TR-FRET, time-resolved FRET; uHTS, ultrahigh-throughput screening.

### References

- Patterson, C. (2018) *The State of the Art of Dementia Research: New Frontiers. An Analysis of Prevalence, Incidence, Cost and Trends*. Alzheimer's Disease International (ADI), London
- Haass, C., and Selkoe, D. (2022) If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? *PLoS Biol.* **20**, e3001694
- The Lancet (2022) Lecanemab for Alzheimer's disease: tempering hype and hope. *Lancet* **400**, 1899
- van Dyck, C. H., Sabbagh, M., and Cohen, S. (2023) Lecanemab in early Alzheimer's disease. *N. Engl. J. Med.* **388**, 1631–1632
- Wang, C., Zong, S., Cui, X., Wang, X., Wu, S., Wang, L., *et al.* (2023) The effects of microglia-associated neuroinflammation on Alzheimer's disease. *Front. Immunol.* **14**, 1117172
- Biber, K., Bhattacharya, A., Campbell, B. M., Piro, J. R., Rohe, M., Staal, R. G. W., *et al.* (2019) Microglial drug targets in AD: opportunities and challenges in drug discovery and development. *Front. Pharmacol.* **10**, 840
- Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., *et al.* (2020) Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. *Nat. Med.* **26**, 769–780
- Rayaprolu, S., Gao, T., Xiao, H., Ramesha, S., Weinstock, L. D., Shah, J., *et al.* (2020) Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer's disease. *Mol. Neurodegener.* **15**, 28
- Sepulveda-Falla, D., Chavez-Gutierrez, L., Portelius, E., Velez, J. I., Dujardin, S., Barrera-Ocampo, A., *et al.* (2021) A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. *Acta Neuropathol.* **141**, 217–233
- Lim, S., Kim, D., Ju, S., Shin, S., Cho, I. J., Park, S. H., *et al.* (2018) Glioblastoma-secreted soluble CD44 activates tau pathology in the brain. *Exp. Mol. Med.* **50**, 1–11
- Wang, Y., Li, L., Wu, Y., Zhang, S., Ju, Q., Yang, Y., *et al.* (2022) CD44 deficiency represses neuroinflammation and rescues dopaminergic

- neurons in a mouse model of Parkinson's disease. *Pharmacol. Res.* **177**, 106133
12. Pinner, E., Gruper, Y., Ben Zimra, M., Kristt, D., Laudon, M., Naor, D., *et al.* (2017) CD44 splice variants as potential players in Alzheimer's disease pathology. *J. Alzheimers Dis.* **58**, 1137–1149
  13. Ponuwei, G. A. (2016) A glimpse of the ERM proteins. *J. Biomed. Sci.* **23**, 35
  14. Michie, K. A., Bermeister, A., Robertson, N. O., Goodchild, S. C., and Curmi, P. M. G. (2019) Two sides of the coin: ezrin/radixin/moesin and Merlin control membrane structure and contact inhibition. *Int. J. Mol. Sci.* **20**, 1996
  15. Al-Momany, A., Li, L., Alexander, R. T., and Ballermann, B. J. (2014) Clustered PI(4,5)P<sub>2</sub> accumulation and ezrin phosphorylation in response to CLIC5A. *J. Cell Sci.* **127**, 5164–5178
  16. Mandal, K. (2020) Review of PIP<sub>2</sub> in cellular signaling, functions and diseases. *Int. J. Mol. Sci.* **21**, 8342
  17. Hamada, K., Shimizu, T., Matsui, T., Tsukita, S., and Hakoshima, T. (2000) Structural basis of the membrane-targeting and unmasking mechanisms of the radixin FERM domain. *EMBO J.* **19**, 4449–4462
  18. Pearson, M. A., Reczek, D., Bretscher, A., and Karplus, P. A. (2000) Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. *Cell* **101**, 259–270
  19. Matsui, T., Maeda, M., Doi, Y., Yonemura, S., Amano, M., Kaibuchi, K., *et al.* (1998) Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. *J. Cell Biol.* **140**, 647–657
  20. Mori, T., Kitano, K., Terawaki, S., Maesaki, R., Fukami, Y., and Hakoshima, T. (2008) Structural basis for CD44 recognition by ERM proteins. *J. Biol. Chem.* **283**, 29602–29612
  21. Weng, X., Maxwell-Warburton, S., Hasib, A., Ma, L., and Kang, L. (2022) The membrane receptor CD44: novel insights into metabolism. *Trends Endocrinol. Metab.* **33**, 318–332
  22. Edwards, S. D., and Keep, N. H. (2001) The 2.7 Å crystal structure of the activated FERM domain of moesin: an analysis of structural changes on activation. *Biochemistry* **40**, 7061–7068
  23. Baell, J. B., and Holloway, G. A. (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *J. Med. Chem.* **53**, 2719–2740
  24. Bosanquet, D. C., Ye, L., Harding, K. G., and Jiang, W. G. (2014) FERM family proteins and their importance in cellular movements and wound healing (review). *Int. J. Mol. Med.* **34**, 3–12
  25. Urciuoli, E., and Peruzzi, B. (2020) Involvement of the FAK network in pathologies related to altered mechanotransduction. *Int. J. Mol. Sci.* **21**, 9426
  26. Yang, Q., Liu, J., and Wang, Z. (2021) 4.1N-Mediated interactions and functions in nerve system and cancer. *Front. Mol. Biosci.* **8**, 711302
  27. Bulut, G., Hong, S. H., Chen, K., Beauchamp, E. M., Rahim, S., Kosturko, G. W., *et al.* (2012) Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. *Oncogene* **31**, 269–281
  28. Hao, J. J., Liu, Y., Kruhlak, M., Debell, K. E., Rellahan, B. L., and Shaw, S. (2009) Phospholipase C-mediated hydrolysis of PIP<sub>2</sub> releases ERM proteins from lymphocyte membrane. *J. Cell Biol.* **184**, 451–462
  29. Yang, X., Boehm, J. S., Yang, X., Salehi-Ashtiani, K., Hao, T., Shen, Y., *et al.* (2011) A public genome-scale lentiviral expression library of human ORFs. *Nat. Methods* **8**, 659–661
  30. Winter, G., Waterman, D. G., Parkhurst, J. M., Brewster, A. S., Gildea, R. J., Gerstel, M., *et al.* (2018) DIALS: implementation and evaluation of a new integration package. *Acta Crystallogr. D Struct. Biol.* **74**, 85–97
  31. Evans, P. R., and Murshudov, G. N. (2013) How good are my data and what is the resolution? *Acta Crystallogr. D Biol. Crystallogr.* **69**, 1204–1214
  32. Vonrhein, C., Tickle, I. J., Flensburg, C., Keller, P., Paciorek, W., Sharff, A., *et al.* (2018) Advances in automated data analysis and processing within autoPROC, combined with improved characterisation, mitigation and visualisation of the anisotropy of diffraction limits using STARANISO. *Acta Crystallogr. A* **74**, A360
  33. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. *J. Appl. Crystallogr.* **40**, 658–674
  34. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 486–501
  35. Bricogne, G., Blanc, E., Brandl, M., Flensburg, C., Keller, P., Paciorek, W., *et al.* (2011) *BUSTER version 2.10.0*
  36. Murshudov, G. N., Skubak, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., *et al.* (2011) REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallogr. D Biol. Crystallogr.* **67**, 355–367
  37. Williams, C. J., Headd, J. J., Moriarty, N. W., Prisant, M. G., Videau, L. L., Deis, L. N., *et al.* (2018) MolProbity: more and better reference data for improved all-atom structure validation. *Protein Sci.* **27**, 293–315
  38. Hayward, S., and Lee, R. A. (2002) Improvements in the analysis of domain motions in proteins from conformational change: DynDom version 1.50. *J. Mol. Graph. Model.* **21**, 181–183
  39. Deng, S. J., Pearce, K. H., Dixon, E. P., Hartley, K. A., Stanley, T. B., Lobe, D. C., *et al.* (2004) Identification of peptides that inhibit the DNA binding, trans-activator, and DNA replication functions of the human papillomavirus type 11 E2 protein. *J. Virol.* **78**, 2637–2641
  40. Puhl, A. C., Bogart, J. W., Haberman, V. A., Larson, J. E., Godoy, A. S., Norris-Drouin, J. L., *et al.* (2020) Discovery and characterization of peptide inhibitors for calcium and Integrin binding protein 1. *ACS Chem. Biol.* **15**, 1505–1516